MedTrace Logo

An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors

NCT07583953 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-05-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of ABO2109 in combination with toripalimab, and to evaluate the immunogenicity, pharmacokinetics, pharmacodynamics, as well as biomarker characteristics of the investigational cancer vaccine. In addition, the antitumor activity of ABO2109 will be assessed during both dose exploration and expansion stages, the accumulative data will support the clinical development of ABO2109.

Conditions

Interventions

BIOLOGICAL

ABO2109 Injection;Toripalimab

Drug: ABO2109 Injection personalized cancer vaccine Drug: Toripalimab Anti-PD-1 monoclonal antibody

BIOLOGICAL

ABO2109 Injection;Toripalimab

Drug: ABO2109 Injection personalized cancer vaccine Drug: Toripalimab Anti-PD-1 monoclonal antibody

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    collaborator OTHER

  • Suzhou Abogen Biosciences Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-17
Primary Completion
2029-01-31
Completion
2031-04-17

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07583953 on ClinicalTrials.gov